An overview on 5α-reductase inhibitors (original) (raw)

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

Claus Roehrborn

Urology, 2002

View PDFchevron_right

Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor

Glenn Cunningham

The Journal of Clinical Endocrinology & Metabolism, 2004

View PDFchevron_right

Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia

Helmut Klocker

World Journal of Urology, 2002

View PDFchevron_right

Efficacy and Safety of Long-Term Treatment with the Dual 5α-Reductase Inhibitor Dutasteride in Men with Symptomatic Benign Prostatic Hyperplasia

Mario Reis

European Urology, 2004

View PDFchevron_right

Pharmacotherapy of benign prostatic hyperplasia: Inhibitor of 5 alpha-reductase

Azam Demirel

International Urology and Nephrology, 1997

View PDFchevron_right

Dihydrotestosterone and the concept of 5a-reductase inhibition in human benign prostatic hyperplasia

Helmut Klocker

World J Urol, 2002

View PDFchevron_right

The use of 5-alpha-reductase inhibitors for the prevention of prostate cancer

Walid El-Ayass

Cancer Biology & Therapy, 2010

View PDFchevron_right

Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases

Samuel Silvestre

The Journal of Steroid Biochemistry and Molecular Biology, 2013

View PDFchevron_right

Steroid 5α-Reductase Inhibitors

Marisa Cabeza

Mini-Reviews in Medicinal Chemistry, 2003

View PDFchevron_right

Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5α-reductase inhibitor

Michael O'Leary

BJU International, 2003

View PDFchevron_right

Selective non-steroidal inhibitors of 5α-reductase type 1

giovanna danza

Journal of Steroid Biochemistry and Molecular Biology, 2004

View PDFchevron_right

Update on the use of dutasteride in the management of benign prostatic hypertrophy

Joe Miller

Clinical Interventions in Aging, 2007

View PDFchevron_right

Effects of 5α-reductase inhibitors on intraprostatic androgens in the rat

Achille Panzeri

Journal of Steroid Biochemistry and Molecular Biology, 1995

View PDFchevron_right

Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature

Antonio Celia

Archivio Italiano di Urologia e Andrologia

View PDFchevron_right

Steroid 5α-Reductase Inhibitors

Alicia Quiroz

Mini-reviews in Medicinal Chemistry, 2003

View PDFchevron_right

Hormonal effects of turosteride, a 5α-reductase inhibitor, in the rat

Achille Panzeri

Journal of Steroid Biochemistry and Molecular Biology, 1993

View PDFchevron_right

Evaluation of New Pregnane Derivatives as 5.ALPHA.-Reductase Inhibitor

Rosa Martinez

CHEMICAL & PHARMACEUTICAL BULLETIN, 2001

View PDFchevron_right

Clinical application of 5α-reductase inhibitors

G. Danza

Journal of Endocrinological Investigation, 2001

View PDFchevron_right

The effects of the dual 5α-reductase inhibitor dutasteride on localized prostate cancer—results from a 4-month pre-radical prostatectomy study

P.eter Pommerville

The Prostate, 2006

View PDFchevron_right

The Effect of 5α-reductase Inhibition with Finasteride and Dutasteride on Bone Mineral Density in Older Men with Benign Prostatic Hyperplasia

Dora Cupic

Collegium Antropologicum, 2014

View PDFchevron_right

Role of 5 alpha-reductase inhibitors in the management of prostate cancer

Javier Hernandez

Clinical Interventions in Aging, 2006

View PDFchevron_right

Comparative study of human steroid 5α-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride

Russell Newton

Life Sciences, 2002

View PDFchevron_right

FCE 28260, a new 5α-reductase inhibitor: In vitro and in vivo effects

Achille Panzeri

Journal of Steroid Biochemistry and Molecular Biology, 1996

View PDFchevron_right

Comparison of the Pharmacological Effects of a Novel Selective Androgen Receptor Modulator, the 5α-Reductase Inhibitor Finasteride, and the Antiandrogen Hydroxyflutamide in Intact Rats: New Approach for Benign Prostate Hyperplasia

Kiwon Chung

Endocrinology, 2004

View PDFchevron_right

Comparison of Clinical Trials With Finasteride and Dutasteride

Lenoo Benoo

View PDFchevron_right

Mechanism-Based Inhibition of Human Steroid 5α-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP−Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor

Margarita Garcia

Journal of The American Chemical Society, 1996

View PDFchevron_right

5?-REDUCTASE Inhibition for Men with Enlarged Prostate

Muta Issa

Journal of the American Academy of Nurse Practitioners, 2007

View PDFchevron_right

Endocrine properties of the testosterone 5α-reductase inhibitor turosteride (FCE 26073)

Achille Panzeri

Journal of Steroid Biochemistry and Molecular Biology, 1994

View PDFchevron_right

New 5α-reductase inhibitors: In vitro and in vivo effects

Elena Ramirez

Steroids, 2005

View PDFchevron_right